Reports Strong First-Quarter Financial Results Vistagen Therapeutics Inc (NASDAQ:VTGN)

0
41

Earnings results for Vistagen Therapeutics Inc (NASDAQ:VTGN)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingMar 2020 , the consensus EPS* forecast has remained the same over the past week at -0.1 and remained the same over the past month at -0.1. none raised and none lowered their forecast. For the fiscal year ending Mar 2020 , the consensus EPS* forecast has remained the same over the past week at -0.52 and remained the same over the past month at -0.52 . none raised and none lowered their forecast.

Analyst Opinion on Vistagen Therapeutics Inc (NASDAQ:VTGN)

3 Wall Street analysts have issued ratings and price targets for Vistagen Therapeutics in the last 12 months. Their average twelve-month price target is $0.85, suggesting that the stock has a possible upside of 58.88%. The high price target for VTGN is $1.00 and the low price target for VTGN is $0.70. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of “Hold.”

Vistagen Therapeutics has received a consensus rating of Hold. The company’s average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings. According to analysts’ consensus price target of $0.85, Vistagen Therapeutics has a potential upside of 58.9% from its current price of $0.54. Vistagen Therapeutics has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Vistagen Therapeutics Inc (NASDAQ:VTGN)

Vistagen Therapeutics does not currently pay a dividend. Vistagen Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Vistagen Therapeutics Inc (NASDAQ:VTGN)

In the past three months, Vistagen Therapeutics insiders have not sold or bought any company stock. Only 12.34% of the stock of Vistagen Therapeutics is held by insiders. Only 4.83% of the stock of Vistagen Therapeutics is held by institutions.

Earnings and Valuation of Vistagen Therapeutics Inc (NASDAQ:VTGN

Earnings for Vistagen Therapeutics are expected to grow in the coming year, from ($0.52) to ($0.44) per share. The P/E ratio of Vistagen Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Vistagen Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Vistagen Therapeutics has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here